TRE-515 could improve the durability of response in combination with KRAS inhibition in patients with advanced non–small cell lung cancer, investigators stated.
|Articles|May 1, 2013
Targeted Therapies in Oncology
- May 2013
- Volume 2
- Issue 3
Full Version of the May 2013 Issue
Full version of the May 2013 Targeted Therapy News
Advertisement
Targeted Therapy Newscovers the most important developments in cancer care today, personalized medicine and targeted therapies. The publication is strongly committed to providing oncology healthcare professionals the information and resources they need to deliver the best possible treatment to their patients
This issue features articles on:
- Key targeted trials being presented at ASCO
- Nongenetic mechanisms of cancer cell diversity and treatment response
- Platinum resistance in ovarian cancer
- HER2-targeted agents in NSCLC
Articles in this issue
over 13 years ago
Bundled Payment: Practice Savior or Killer?over 13 years ago
Notch Holds Promise, but Presents Obstacles as Cancer Targetover 13 years ago
Spotlight on Novel Agents in Early Developmentover 13 years ago
Treating Elderly Patients With CLLover 13 years ago
Biomarkers Still Needed in Prostate CancerAdvertisement
Related to this article
FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus bendamustine-rituximab.
Submission of a new drug application for zipalertinib plus chemotherapy has begun under the FDA's RTOR program, based on phase 3 REZILIENT3 data showing a 6-month PFS gain.
Insurance hurdles and steep out-of-pocket costs often delay or prevent patients from filling specialty oral blood cancer drugs, even after eventual approvals.
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
The MUC16xCD3 bispecific antibody showed a 73% response rate in phase 1/2 trial; the sponsor announced plans for a potential registrational cohort and phase 3 trial.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Giredestrant plus everolimus reduced the risk of progression or death by 44% in the ITT population and 62% in ESR1-mutated disease in phase 3 evERA data published in NEJM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
2
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
3
NDA Submission Initiated for Zipalertinib Combo in EGFR Exon 20+ NSCLC
4
FDA Grants Fast Track Designation to TRE-515 for KRAS G12C NSCLC
5